RecruitingPhase 2NCT06357234

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

A Randomized Controlled Trial Comparing Aprepitant to Standard of Care for Postoperative Nausea and Vomiting Prophylaxis in Children and Adolescents Undergoing Scoliosis Surgery: The APRE-PONV Trial


Sponsor

IWK Health Centre

Enrollment

100 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).


Eligibility

Min Age: 8 YearsMax Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aprepitant and a drug called Placebo for people with anesthesia, nausea and vomiting, postoperative, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 8 Years to 19 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAprepitant

Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1

DRUGPlacebo

Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1


Locations(1)

IWK Health Sciences Center

Halifax, Nova Scotia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06357234


Related Trials